Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 18 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti- neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field.

Morbidelli, L. (a cura di). (2022). ANTIANGIOGENIC DRUGS AS CHEMOSENSITIZERS IN CANCER THERAPY. Elsevier/AP [10.1016/C2020-0-03561-9].

ANTIANGIOGENIC DRUGS AS CHEMOSENSITIZERS IN CANCER THERAPY

Morbidelli Lucia
Supervision
2022

Abstract

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 18 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti- neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds—molecules that inhibit the growth of vessels inside a tumor—together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field.
978-0-323-90190-1
Morbidelli, L. (a cura di). (2022). ANTIANGIOGENIC DRUGS AS CHEMOSENSITIZERS IN CANCER THERAPY. Elsevier/AP [10.1016/C2020-0-03561-9].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1205919